Your browser doesn't support javascript.
COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.
van Eijk, Larissa E; Binkhorst, Mathijs; Bourgonje, Arno R; Offringa, Annette K; Mulder, Douwe J; Bos, Eelke M; Kolundzic, Nikola; Abdulle, Amaal E; van der Voort, Peter Hj; Olde Rikkert, Marcel Gm; van der Hoeven, Johannes G; den Dunnen, Wilfred Fa; Hillebrands, Jan-Luuk; van Goor, Harry.
  • van Eijk LE; Department of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Binkhorst M; Department of Paediatrics, Subdivision of Neonatology, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, The Netherlands.
  • Bourgonje AR; Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Offringa AK; Microbiology and System Biology, Netherlands Organisation for Applied Scientific Research, Zeist, The Netherlands.
  • Mulder DJ; Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Bos EM; Department of Neurosurgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Kolundzic N; Stem Cell Laboratory, Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
  • Abdulle AE; Assisted Conception Unit, Guy's Hospital, London, UK.
  • van der Voort PH; Department of Internal Medicine, Division of Vascular Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Olde Rikkert MG; Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • van der Hoeven JG; Department of Geriatric Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • den Dunnen WF; Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Hillebrands JL; Department of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • van Goor H; Department of Pathology and Medical Biology, Division of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
J Pathol ; 254(4): 307-331, 2021 07.
Article in English | MEDLINE | ID: covidwho-1084377
ABSTRACT
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID-19 cases are characterised by a mild, self-limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi-organ failure (MOF). Progression of COVID-19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS-CoV-2 infection and contribute to organ-specific tissue damage. In this respect, dissecting currently available knowledge of COVID-19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune-mediated pathways during SARS-CoV-2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID-19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence-based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID-19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID-19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID-19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adaptive Immunity / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: J Pathol Year: 2021 Document Type: Article Affiliation country: Path.5642

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adaptive Immunity / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: J Pathol Year: 2021 Document Type: Article Affiliation country: Path.5642